SML Ezplex SARS-CoV-2 G Kit Owner’s Manual
- June 7, 2024
- SML
Table of Contents
Ezplex SARS-CoV-2 G Kit
Ezplex SARS-CoV-2 G Kit
Ezplex SARS-CoV-2 G Kit
For Emergency Use Authorization (EUA) only. For in vitro diagnostic use only.
For prescription use only.
Instructions for Use (IFU)
SML Genetree Co. Ltd. 255 Baumoe-ro, Seocho-gu, Seoul, 06740, Republic of
Korea
Ezplex SARS-CoV-2 G Kit
Page 1 / 29
IFU013 (rev.3, April 2021)
Table of Contents
I. Intended Use II. Summary and Explanation III. Principles of the Procedure
IV. Kit Components and Packaging Specifications V. Materials Required but Not
Provided VI. Instruments VII. Storage & Handling Conditions VIII. Warnings and
Precautions IX. Collection, Storage and Shipment of Specimens X. Test
Procedure XI. Quality Control XII. Genetree Viewer Software Analysis XIII.
Interpretation of Results XIV. Limitations XV. Conditions of Authorization for
the Laboratory XVI. Performance Evaluation XVII. FDA SARS-C0V-2 Reference
Panel Testing Appendix A: Pooling Monitoring Plan Appendix B: Additional Label
XVIII. References XIX. Symbols and Information XX. Technical Support
Proprietary Name: Ezplex SARS-CoV-2 G Kit
Ezplex SARS-CoV-2 G Kit
Page 2 / 29
Ezplex SARS-CoV-2 G Kit
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
I. Intended Use
The Ezplex SARS-CoV-2 G Kit is a real-time RT-PCR in vitro diagnostic test
intended for the qualitative detection of nucleic acid from SARS-CoV-2 in
nasopharyngeal swabs, oropharyngeal swabs, and sputum specimens collected from
individuals suspected of COVID-19 by their healthcare provider. Testing is
limited to laboratories certified under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform
high complexity tests.
This test is also for the qualitative detection of nucleic acid from the SARS-
CoV-2 in pooled specimens containing up to five individual nasopharyngeal or
oropharyngeal swabs where each specimen is collected by a healthcare provider
using individual vials containing transport media from individuals suspected
of COVID-19 by their health care provider. Negative results from pooled
testing should not be treated as definitive. If a patient’s clinical signs and
symptoms are inconsistent with a negative result or if results are necessary
for patient management, then the patient should be considered for individual
testing. Specimens included in pools with a positive, inconclusive, or invalid
result must be tested individually prior to reporting a result. Specimens with
low viral loads may not be detected in specimen pools due to the decreased
sensitivity of pooled testing.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is
generally detectable in upper respiratory specimens during the acute phase of
infection. Positive results are indicative of the presence of SARS-CoV-2 RNA;
clinical correlation with patient history and other diagnostic information is
necessary to determine patient infection status. Positive results do not rule
out bacterial infection or co-infection with other viruses. The agent detected
may not be the definite cause of disease. Laboratories within the United
States and its territories are required to report all results to the
appropriate public health authorities.
Negative results do not preclude SARS-CoV-2 infection and should not be used
as the sole basis for patient management decisions. Negative results must be
combined with clinical observations, patient history, and epidemiological
information.
The Ezplex SARS-CoV-2 G Kit is intended for use by qualified and trained
clinical laboratory personnel specifically instructed and trained in the
techniques of real-time PCR and in vitro diagnostic procedures. The Ezplex
SARS-CoV-2 G Kit is only for use in the United States under the Food and Drug
Administration’s Emergency Use Authorization.
II. Summary and Explanation
Coronaviruses are a large family of viruses which may cause illness in animals
or humans. In humans, several coronaviruses are known to cause respiratory
infections ranging from the common cold to more severe diseases such as Middle
East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
The most recently discovered coronavirus, SARS-
Ezplex SARS-CoV-2 G Kit
Page 3 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
CoV-2, causes the associated coronavirus disease COVID-19. This new virus and
disease were unknown before the outbreak began in Wuhan, China, in December
2019.1
The most common symptoms of COVID-19 are fever, tiredness, and dry cough. Some
patients may have aches and pains, nasal congestion, runny nose, sore throat,
new loss of taste or smell, or diarrhea. These symptoms are usually mild and
begin gradually. Some people become infected but don’t develop any symptoms
and don’t feel unwell. The disease can spread through respiratory droplets
produced when an infected person coughs or sneezes. These droplets can land in
the mouths or noses of people who are nearby or possibly be inhaled into the
lungs.2 These droplets also can land on objects and surfaces around the
person.3 Other people may acquire SARS-CoV-2 by touching these objects or
surfaces, then touching their eyes, nose, or mouth.
The virus that causes COVID-19 is infecting people and spreading easily from
person to person. On March 11, 2020, the COVID-19 outbreak was characterized
as a pandemic by the World Health Organization (WHO).4,5
III. Principles of the Procedure
The Ezplex SARS-CoV-2 G Kit uses TaqMan-based real-time reverse transcription
polymerase chain techniques to conduct in vitro reverse transcription of SARs-
CoV-2 RNA, DNA amplification and fluorescence detection. The assay targets
specific genomic regions of the SARS-Co-V-2 RdRP and N genes. Nucleic acid is
isolated and purified from respiratory specimens using the Qiagen QIAamp® DSP
Viral RNA Mini Kit. The purified nucleic acid is then reverse transcribed into
cDNA using the Ezplex SARS-CoV-2 G kit. The cDNA is then subsequently
amplified using either the CFX96 Dx Real-time PCR instrument (Bio-Rad) or the
Applied Biosystems 7500 Real-time PCR instrument (ThermoFisher Scientific).
During this process, the probe anneals to a specific target sequence located
between the forward and reverse primers. During the extension phase of the PCR
cycle, the 5′ nuclease activity of Taq polymerase degrades the probe, causing
the reporter dye to separate from the quencher dye, generating a fluorescent
signal. With each cycle, additional reporter dye molecules are cleaved from
their respective probes, increasing the fluorescence intensity. Fluorescence
intensity is monitored at each PCR cycle.
The negative control included in the kit serves as a general control for
exogenous nucleic acid contamination and is used to monitor cross-
contamination during the RNA extraction and PCR reaction setup steps. It
should be run with each batch of tests.
The positive control included in the kit consists of synthesized plasmid DNA
for each gene target and is used to monitor for the presence of inhibitors and
the efficiency of the polymerase chain reaction. It should be run with each
batch of tests.
An internal control is utilized to ensure that clinical specimens are
successfully amplified and
Ezplex SARS-CoV-2 G Kit
Page 4 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
detected. This control consists of plasmid DNA that was synthesized to include
a portion of the human BCR activator of RhoGEF and GTPase (BCR) gene. This
control is added to the reaction master mixture during PCR preparation
procedure.
The Ezplex SARS-CoV-2 G Kit does not include an internal control for RNA
extraction/recovery or transcription. A known SARS-CoV-2 positive specimen or
specimen containing SARS-CoV-2 RNA (i.e., in vitro transcript or pseudovirus)
must be tested with every batch of patient specimens to monitor the integrity
of these process steps.
IV. Kit Components and Packaging Specifications
Catalog Number: GNT2011-1 100 tests/kit
No.
Component Name*
Volume
1
RQ Mixture
1 vial, 1000uL
2
P+P
3
Positive Control (PC)
1 vial, 500uL 1 vial, 50uL
Main Ingredients
DNA Taq polymerase, Reverse Transcriptase, dNTPs with dUTP, Magnesium
Chloride, Potassium, Uracil N-glycosylase
Tris-HCl, EDTA, Oligonucleotide primers specific for SARS-CoV-2 virus,
Fluorescentlabeled oligonucleotide probe specific for SARSCoV-2 virus
Tris-HCl, EDTA, Synthesized DNA control specific for SARS-CoV-2 virus
4
Negative Control (NC)
1 vial, 50uL Double Distilled Water
5
Internal Control (IC)
1 vial, 20uL
Tris-HCl, EDTA, Synthesized DNA internal control
*RQ Mixture: Real-time Quantitative PCR Mixture; P+P : Probe + Primer
Ezplex SARS-CoV-2 G Kit
Page 5 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Catalog Number: GNT-2011-2 200 tests/kit
No.
Kit Component*
Volume
1
RQ Mixture
2 vials, 1000uL
2
P+P
2 vials, 500uL
3
Positive Control (PC)
2 vials, 50uL
Main Ingredients
DNA Taq polymerase, Reverse Transcriptase, dNTPs with dUTP, Magnesium
Chloride, Potassium, Uracil N-glycosylase Tris-HCl, EDTA, Oligonucleotide
primers specific for SARS-CoV-2 virus, Fluorescent-labeled oligonucleotide
probespecific for SARS-CoV-2 virus
Tris-HCl, EDTA, Synthesized DNA control specific for SARS-CoV-2 virus
4
Negative Control (NC) 2 vials, 50uL
Double Distilled Wa ter
5
Internal Control )IC)
2 vials, 20uL
Tris-HCl, EDTA, Synthesized DNA internal control
*RQ Mixture: Real-time Quantitative PCR Mixture; P+P : Probe + Primer Optional Materials Provided: · Genetree Viewer Software (CAT No. GNT2011-3)
V. Materials Required But Not Provided
No. Name
1 For Bio-Rad instrument: any applicable 96 well PCR plate plastics for CFX96
Dx system
2 For Bio-Rad instrument: any applicable PCR plate sealing film for CFX96 Dx
system
3 For ThermoFisher Scientific instrument: microAmp Optical Adhesive Film
4 For ThermoFisher Scientific instrument: microAmp Optical 96-well Reaction
Plate
5 For ThermoFisher Scientific instrument: microAmp Optical 8-tubestrip(0.2mL)
6 For ThermoFisher Scientific instrument: microAmp Optical 8-cap Strip
7 Qiagen QIAamp® DSP Viral RNA Mini Kit
CAT No. MLL9651 MSB1001 4311971 N8010560 431567 4323032 61904
Company Bio-Ra d
Bio-Ra d
ThermoFisher Scientific ThermoFisher Scientific ThermoFisher Scientific
ThermoFisher Scientific Qia gen
8 Known SARS-CoV-2 positivespecimen or
MBC137-R
specimen containing SARS-CoV-2 RNA(in vitro (Recommended)
transcript or pseudovirus) to control for
Vircell
extraction/recovery or transcription
9 Computer for installation of GenetreeViewer Analysis Software
- Microprocessor: Intel(R) i3 3.5 GHz or above 2) Memory: 4 GB or larger; 3) Microsoft Windows 7 or above; 4) more than 1 USB port
Ezplex SARS-CoV-2 G Kit
Page 6 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
VI. Instruments
PCR Instruments validated for use with the Ezplex SARS-CoV-2 G Kit: · CFX96 Dx
Real-time PCR Instrument with 1.6 or 3.1 or later versions of CFX Manager
(Bio-Rad) OR · ABI 7500 Real-time PCR Instrument with 2.3 or later versions of
7500 software
(ThermoFisher Scientific)1
VII. Storage and Handling Conditions
· All kit materials should be stored at -20 °C opened and unopened. · Use the
reagents before the expiration date shown on the labeling. · Completely thaw
the reagents before use. · Repeated thawing and freezing should be avoided. It
should not exceed 5 freeze-thaw cycles.
VIII. Warnings and Precautions
· For in vitro diagnostic use. For use under an Emergency Use Authorization
(EUA) only. · This product has not been FDA cleared or approved; but has been
authorized by the FDA
under an Emergency Use Authorization (EUA) for use by laboratories certified
under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C.
§263a, that meet requirements to perform high complexity tests. · This product
has been authorized only for the detection of nucleic acid from SARS-CoV2, not
for any other viruses or pathogens. · The emergency use of this product is
only authorized for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of in vitro diagnostics for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal
Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the d
eclaratio n is terminated or authorization is revoked sooner. · Handle all
specimens as if infectious using safe laboratory procedures. Refer to Interim
· Laboratory Biosafety Guidelines for Handling and Processing Specimens
Associated with2019-nCoV. https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-
biosafetyguidelines.html.
· Specimens may be infectious. Use Universal Precautions when performing this
assay. Proper handling and disposal methods should be established by the
laboratory director. Only personnel adequately trained in handling infectious
materials should be permitted to perform this diagnostic procedure.6
· Use appropriate personal protective equipment when collecting and handling
specimens from individuals suspected of being infected with SARS-CoV-2 as
outlined in CDC Interim Laboratory Biosafety Guidelines for Handling and
Processing Specimens
Ezplex SARS-CoV-2 G Kit
Page 7 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Associated with 2019 Novel Coronavirus (2019-nCoV). · Wear disposable,
powderless gloves, protective eye wear, and laboratory coats when
handling specimens and reagents. Wash hands thoroughly after handling
specimens and reagents. · Dispose of all material that has come into contact
with specimens and reagents in accordance with applicable national,
international, and regional regulations. · Maintain proper storage conditions
during specimen shipping to ensure the integrity of the specimen. Specimen
stability under shipping conditions other than those recommended has not been
evaluated. · Avoid cross-contamination during the specimen handling steps.
Specimens can contain extremely high levels of virus or other organisms.
Ensure that specimen containers do not come in contact with one another, and
discard used materials without passing them over any open containers. Change
gloves if they come in contact with specimens. It is recommended to use
sterile disposable filter-tips to aspirate reagents and specimens. · Do not
use the reagents and controls after the expiration date. · Do not mix reagents
from different lots. · Since the plasmid DNA in the positive control can
degrade, it is recommended that the reagents shall be divided into amounts
required for 1-2 tests and stored in a freezer. · Only the Qiagen QIAamp® DSP
Viral RNA Mini Kit can be used with the Ezplex SARSCoV-2 Kit for nucleic acid
extraction. · Only the Bio-Rad CFX Dx Real-time PCR Instrument and the
ThermoFisher Scientific ABI 7500 Real-time PCR Instrument can be used with the
Ezplex SARS-CoV-2 Kit. These instruments should be calibrated regularly
according to instrument’s instructions to eliminate cross-talks between
channels. · The Ezplex SARS-CoV-2 Kit uses PCR-based technology and testing
should be conducted in three separate areas: reagent preparation area,
specimen preparation area and amplification area. Protective equipment
accessories (goggles, work clothes, hats, shoes, gloves, etc.) should be worn
during operation and protective equipment accessories should be changed when
entering and leaving different work areas. Protective equipment accessories in
each work area are not interchangeable. · Store assay components at the
recommended storage condition. · Quality control requirements must be
performed in conformance with local, state, and/or federal regulations or
accreditation requirements and your laboratory’s standard quality control
procedures. · Contamination may occur if carryover of specimens is not
adequately controlled during specimen pool preparation, handling, and
processing. · Testing of pooled specimens may impact the detection capability
of the SARS-CoV-2 assay and impact sensitivity.
IX. Collection, Storage and Shipment of Specimens
Ezplex SARS-CoV-2 G Kit
Page 8 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Only upper respiratory specimens collected in VTM (such as nasopharyngeal and
oropharyngeal swabs) and sputum specimens can be used with the test. Note:
Only nasopharyngeal/oropharyngeal swabs in viral transport media (VTM) have
been validated for pooling. Ensure that sufficient specimen volumes of any
upper respiratory specimen that is utilized for pooling also have enough
volume for additional individual testing.
A. Specimen Collection Use only synthetic fiber swabs with plastic shafts. Do
not use calcium alginate swabs or swabs with wooden shafts, as they may
contain substances that inactivate some viruses and inhibit PCR testing. Place
swabs immediately into sterile tubes containing3 ml of viral transport media
(VTM). For initial testing, nasopharyngeal swab specimens are recommended.
Collection of oropharyngeal swabs is a lower priority and is acceptable if
other swabs are not available.
· Nasopharyngeal swab (NP): Insert a swab into nostril parallel to the palate.
Swab should reach depth equal to distance from nostrils to outer opening of
the ear. Leave swab in place for several seconds to absorb secretions. Slowly
remove swab while rotating it.
· Oropharyngeal swab (e.g., throat swab, OP): Swab the posterior pharynx,
avoiding the tongue.
· Sputum : Educate the patient about the difference betweensputum and oral
secretions. Have the patient rinse the mouth with water and then expectorate
deep cough sputum directly into a sterile screw-cap collection cup or sterile
dry container.
B. Specimen Storage A sample collection device is not a part of the assay kit.
Patient samples must be collected according to appropriate laboratory
guidelines. All testing for COVID-19 should be conducted in consultation with
a healthcare provider. We recommend using CDC guidelines for sample collection
of respiratory specimens and sample storage
(https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-
specimens.html). Specimens should be processed within 48 hours from collection
and stored at 2-8°C during that time. If the specimens cannot be tested within
48 hours, samples should be stored frozen at -70ºC or colder.
C. Shipping Specimens must be packaged, shipped, and transported according to
the current edition of the International Air Transport Association (IATA)
Dangerous Goods Regulation External Icon. Store specimens at 2-8°C and ship
overnight to the lab on ice pack. If a specimen is frozen at 70°C ship,
overnight to the lab on dry ice. Additional useful and detailed information on
packing, shipping, and transporting specimens can be found at Interim
Laboratory Biosafety Guidelines for Handling and Processing Specimens
Associated with Coronavirus Disease 2019 (COVID-19).
D. For more information, refer to: Interim Guidelines for Collecting,
Handling, and Testing Clinical Specimens from Persons for
Ezplex SARS-CoV-2 G Kit
Page 9 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Coronavirus Disease 2019 (COVID-19) https://www.cdc.gov/coronavirus/2019-nCoV
/guidelines-clinical-specimens.html Interim Laboratory Biosafety Guidelines
for Handling and Processing Specimens Associated with Coronavirus Disease 2019
(COVID-19) https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-
guidelines.html
E. Ensure that sufficient specimen volumes of any upper respiratory specimen
that is utilized for pooling also has enough volume for additional individual
testing.
F. Specimen Pooling-Determining Appropriate Strategy for Implementation and
Monitoring When considering specimen pooling, laboratories should evaluate the
appropriateness of a pooling strategy based on the positivity rate in the
testing population and the efficiency of the pooling workflow. Refer to
Appendix A of these instructions for Use for additional information prior to
implementation of specimen pooling.
G. Specimen Preparation 1. Specimens for Individual Testing · Nucleic acid
should be isolated and purified from nasopharyngeal swabs, and oropharyngeal
swabs, and a sputum specimens using the QIAamp® DSP Viral RNA Mini Kit. ·
Prior to the start of the nucleic acid extraction, an additional negative
clinical sample should be
prepared and spiked with a known SARS-CoV-2 control. This functions as an
extraction control to assess extraction reagent integrity and successful RNA
extraction. · Ensure homogenous mixing of prepared specimens. · Utilize 140 L
of clinical sample and elute with 50 L of Buffer AVE from the QIAamp® DSP
Viral RNA Mini Kit. If the extracted RNA cannot be used immediately, store at
2 to 8 ° C for up to 24 hours or at -70 ° C for up to 1 month. · Refer to the
QIAamp® DSP Viral RNA Mini Kit Handbook for the protocol for extracting RNA
using the QIAamp® DSP Viral RNA Mini Kit.
2. Pooled Specimens Only upper respiratory specimens collected in VTM, such
as nasopharyngeal and oropharyngeal swabs, may be tested with pooled
specimens. · Obtain an empty tube (molecular grade sterile test tube). ·
Determine the appropriate volume required from each individual specimen based
on the
pool size being implemented. The required specimen to extraction ratio in the
assay test specimen must be maintained for specimen pooling. The minimum
combined volume of individual specimens pooled prior to transferring is 250
µL. The same volume of each specimen included in the pool needs to be used. ·
Carefully transfer the determined volume of each individual specimen from the
specimen collection container to the empty sterile tube. · An additional
negative clinical sample should be prepared and spiked with known SARSCoV-2
control. It functions as an extraction control to assess extraction reagent
integrity and successful RNA extraction.
Ezplex SARS-CoV-2 G Kit
Page 10 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
· Ensure homogenous mixing of each prepared specimen pool. · Utilize 140 L of
pooled clinical sample and elute with 50 L of Buffer AVE from the
QIAamp® DSP Viral RNA Mini Kit. If the extracted RNA cannot be used
immediately, store at 2 to 8 for up to 24 · hours or at -70 for up to 1 month.
· Refer to the QIAamp® DSP Viral RNA Mini Kit Handbook for the protocol for
extracting RNA using the QIAamp® DSP Viral RNA Mini Kit
NOTE: Retain the individual specimens for additional testing, if required.
X. Test Procedure
A. Nucleic Acid Extraction The QIAamp® DSP Virus Viral RNA mini Kit (Qiagen
GmbH) must be used for RNA extraction and users shall follow the protocol
included in the Kit Instructions for Use. After extraction, RNA if not used
immediately should be divided into amounts required for 1-2 tests and stored
at 70 since RNA can degrade.
B. Real-time PCR Amplification 1. Reagent Master Mix Solution Preparation
a. Refer to the table below and prepare the PCR master mix solution according
to the number of specimens/controls to be tested.
Component RQ Mixture (Real time QuantitativeMixture)
P + P (Probe + Primer) Internal control Tota l
Volume (uL) per Specimen/Control 10 5 0.1 15.1
b. Pipette 15uL of PCR master mix solution into each 96-well PCR plate or
8-cap strip. Add 5uL of the extracted RNA specimen into each 96-well PCR plate
or 8-cap strip.
c. Also, add 5 uL each of the positive control and negative control into each
96-well PCR plate or 8-cap strip.
d. If the 96-well PCR plate is used for the preparation, seal the top of the
plate thoroughly to prevent the liquid from spilling or leaking.
e. If the 8-cap strip is used for the preparation, make sure that every cap is
tightly closed on the top of the strips.
Ezplex SARS-CoV-2 G Kit
Page 11 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
f. Centrifuge the 96-well PCR plate or 8-cap strip to make sure that all
liquids are placed at the bottom.
g. Each batch of samples tested should include the following controls:
positive control, negative control, and extraction/transcription control.
2. PCR Instrument Set Up a. Set up the Bio-Rad or Applied Biosystems PCR
Instrument according to their respective Instrument Reference Guide/Manual
using the cycling specifications below:
Step Hold Cycle
Temperature / Time
25 / 2 min 50 / 30 min 95 / 5 min 95 / 15 sec 60 / 45 sec
Cycle 1 Cycle 40 Cycles
b. Set up fluorescent thresholds for detection targets per the table below.
c. The threshold should be adjusted to fall within the exponential phase of
the fluorescence curves and above any background noise signal. The procedure
chosen for setting the threshold should be used consistently.
Device
Bio-Rad CFX96 Dx ThermoFisher Scientific
AB7500
FAM 500 0.4
Cy5
VIC(HEX)
250
500
0.1
0.05
d. Add the prepared 96-well PCR plate or 8-cap strips to the PCR instrument and run the BioRad or Applied Biosystems PCR Instrument according to their respective Instrument Reference Guide/Manual.
XI. Quality Control
A Positive Control and Negative Control are provided with the Kit and should
be run with each batch of specimens. An internal control [plasmid DNA
synthesized to include a portion of the human BCR activator of RhoGEF and
GTPase (BCR) genes] is provided with the kit and is utilized to ensure that
each clinical specimen is successfully amplified and detected. This control is
added to the reaction master mix during PCR preparation procedure. The Ezplex
SARS-CoV-2 G Kit does not include an internal control for RNA
extraction/recovery or transcription. A
Ezplex SARS-CoV-2 G Kit
Page 12 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
known SARS-CoV-2 positive specimen or specimen containing SARS-CoV-2 RNA
(i.e., in vitro transcript or pseudovirus) must be tested with every batch of
patient specimens to monitor the integrity of these process steps.
XII. Genetree Viewer Software Analysis
NOTE: Please contact technicalsupport@smlgenetree.com’ to acquireGenetree
Viewer’ software prior to running the Ezplex SARS-CoV-2 G Test. Please refer
to the Genetree Viewer Software Operators Manual for more detailed
information.
A. General Description of the Software and Example Screens
No.
Description
Positive/Negative results by well are indicated in ‘+’, ‘-‘ respectively. Invalid results by well are indicated in ‘?’ respectively.
Ct and fluorescent values of the results for each well are plotted on a graph.
Ct values of the results for each well are indicated numerically and qualitativeresults areprinted.
Analysis results are converted into an excel spreadsheet.
Ezplex SARS-CoV-2 G Kit
Page 13 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
XIII. Interpretation of Results
Assessment of clinical specimen test results should be performed after the
positive and negative controls have been examined and determined to be valid
and acceptable. If the controls are not valid, the patient results cannot be
interpreted.
a. The table below lists the expected results for the kit with valid positive
control and negative control.
FAM Ct (RdRp)
<40 <40
Neg Neg Neg
CY5 Ct (N) <40 Neg <40 Neg Neg
VIC/HEX Ct (IC) Any Any Any <38
38 or Neg
Result*
Comment
Positive Inconclusive Inconclusive
Negative
SARS-CoV-2 RNA is detected
Further confirmatory testing may be conducted if clinically indicated
Further confirmatory testing may be conducted if clinically indicated
SARS-CoV-2 RNA is not detected
Invalid
Retest after re-extraction
· The result is judged as Positive only when both the RdRp and N genes are
detected. · Further confirmatory testing may be conducted if clinically
indicated if the result is judged
as “Inconclusive”. · Retesting after re-extraction is necessary if the result
is judged as “Invalid.” If the re-tested
Ezplex SARS-CoV-2 G Kit
Page 14 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
result remains invalid, report the invalid result and consider collecting a
fresh sample and retesting if clinically indicated.
b. Interpretation of Results for Pooled Specimens Negative: For sample pools
yielding negative results, all samples making up that pool are presumed to be
negative. Negative results from pooled specimen testing should not be treated
as definitive. If the patient’s clinical signs and symptoms are inconsistent
with a negative result and results are necessary for patient management, then
the patient should be considered for individual testing. The utilization of
specimen pooling should be indicated for any specimens with reported negative
results. Positive: Specimens in a positive specimen pool must be tested
individually prior to reporting a result. Specimens with low viral loads may
not be detected in specimen pools due to the decreased sensitivity of pooled
testing. Invalid: Specimens with an invalid pool result must be tested
individually prior to reporting a result. However, in instances of an invalid
run, repeat extraction and testing of the specimen pool may be appropriate
depending on the laboratory workflow and required result reporting time.
Inconclusive: Specimens with an inconclusive pool result must be tested
individually prior to reporting a result. Specimens with an inconclusive
result upon individual testing may need further confirmatory testing if
clinically indicated.
XIV. Limitations
· The Ezplex SARS-CoV-2 G Kit has been analytically validated for use with
nasopharyngeal and oropharyngeal swabs in VTM and sputum specimens run on the
Bio-Rad CFX96 Dx Real-Time PCR and ABI 7500 Real-time PCR Instrument and
utilizing the Qiagen QIAamp® DSP Viral RNA Mini Kit for RNA extraction. This
assay has been clinically validated for use with nasopharyngeal/oropharyngeal
swabs in VTM and sputum specimens run on the Bio-Rad CFX96 Dx Real-Time PCR
utilizing the Qiagen QIAamp® DSP Viral RNA Mini Kit for RNA extraction.
· Based on the in-silico analysis, SARS-CoV and other SARS-like coronaviruses
in the same subgenus (Sarbecovirus) as SARS-CoV-2 may cross-react with the N
gene in the Ezplex assay. SARS-CoV is not known to be currently circulating in
the human population, and therefore is unlikely to be present in patient
specimens.
· The clinical performance has not been established in all circulating
variants but is anticipated to be reflective of the prevalent variants in
circulation at the time and location of the clinical evaluation. Performance
at the time of testing may vary depending on the variants circulating,
including newly emerging strains of SARS-CoV-2 and their prevalence, which
change over time.
· The procedures in this handbook must be followed, as described. Any
deviations may result in assay failure or may cause erroneous results.
· Use of this assay is limited to personnel who are trained in the procedure.
Failure to follow these instructions may result in erroneous results.
· Reliable results are dependent on adequate specimen collection, transport,
storage, and processing.
Ezplex SARS-CoV-2 G Kit
Page 15 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
· Good laboratory practices are required to ensure the performance of the kit,
with care required to prevent contamination of the kit components. Components
should be monitored for contamination and any components thought to have
become contaminated should be discarded as standard laboratory waste in a
sealed pouch or zip-lock plastic bag.
· All specimens should be handled as if they are infectious following proper
biosafety precautions.
· False negative results may be caused by: o Unsuitable collection, handling
and/or storage of specimens o Specimen outside of viremic phase o Failure to
follow procedures in this handbook o Use of unauthorized extraction kit or PCR
platforms
· False positive results may be caused by: o Unsuitable handling of specimens
containing high concentration of COVID-19 viral RNA or positive control
template o Unsuitable handling of amplified product
· All results should be interpreted by a health care professional in the
context of patient medical history and clinical symptoms.
· This test cannot rule out diseases caused by other pathogens. · Negative
results do not preclude SARS-CoV-2 infections and should not be used as the
sole
basis for treatment or other management decisions. · A positive result
indicates the detection of nucleic acid from the relevant virus. Nucleic
acid may persist even after the virus is no longer viable. · Specimen pooling
has only been validated using upper respiratory
(nasopharyngeal/oropharyngeal) swabs in VTM. · Specimens should only be pooled
when testing demand exceeds laboratory capacity and/or
when testing reagents are in short supply.
XV. Conditions of Authorization for the Laboratory
The Ezplex SARS-CoV-2 G Kit Letter of Authorization, along with the authorized
Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients,
and authorized labeling are available on the FDA website: https://www.fda.gov
/medical-devices/coronavirus-disease-2019covid-19-emergency-use-
authorizations-medical-devices/vitro-diagnostics-euas
However, to assist clinical laboratories using the Ezplex SARS-CoV-2 G kit,
the relevant Conditions of Authorization are listed below.
1. Authorized laboratories* using the Ezplex SARS-CoV-2 G kit must include
with result reports, all authorized Fact Sheets. Under exigent circumstances,
other appropriate methods for disseminating these Fact Sheets may be used,
which may include mass media.
2. Authorized laboratories using specimen pooling strategies when testing
patient specimens with
Ezplex SARS-CoV-2 G Kit
Page 16 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
the Ezplex SARS-CoV-2 G kit must include with negative test result reports for
specific patients whose specimen(s) were the subject of pooling, a notice that
pooling was used during testing and that “Patient specimens with low viral
loads may not be detected in specimen pools due to the decreased sensitivity
of pooled testing.”
3. Authorized laboratories using the Ezplex SARS-CoV-2 G kit must use the
Ezplex SARSCoV-2 G kit as outlined in the authorized labeling. Deviations from
the authorized procedures, including the authorized instruments, authorized
extraction methods, authorized clinical specimen types, authorized control
materials, authorized other ancillary reagents and authorized materials
required to perform the Ezplex SARS-CoV-2 G kit are not permitted.
4. Authorized laboratories implementing pooling strategies for testing
patient specimens must use the “Specimen Pooling-Determining Appropriate
Strategy for Implementation and Monitoring” available in the authorized
labeling to evaluate the appropriateness of continuing to use such strategies
based on the recommendations in the protocol.
5. Authorized laboratories that receive the Ezplex SARS-CoV-2 G kit must
notify the relevant public health authorities of their intent to run the test
prior to initiating testing. 6. Authorized laboratories using the Ezplex SARS-
CoV-2 G kit must have a process in place for reporting test results to
healthcare providers and relevant public health authorities, as appropriate.
7. Authorized laboratories must collect information on the performance of the
test and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-
Reporting@fda.hhs.gov) and SML Genetree (via email: info@genetree.com or
genetree@genetree.co.kr) any suspected occurrence of false positive or false
negative results and significant deviations from the established performance
characteristics of the test of which they become aware.
8. All laboratory personnel using the test must be appropriately trained in
RT-PCR techniques and use appropriate laboratory and personal protective
equipment when handling this kit and use the test in accordance with the
authorized labeling.
9. SML Genetree, its authorized distributor(s) and authorized laboratories
using the SARS-CoV2 G kit must ensure that any records associated with this
EUA are maintained until otherwise notified by FDA. Such records will be made
available to FDA for inspection upon request.
10. Authorized laboratories must keep records of specimen pooling strategies
implemented including type of strategy, date implemented, and quantities
tested, and test result data generated as part of the Protocol for Monitoring
of Specimen Pooling Strategies. For the first 12 months from the date of their
creation, such records must be made available to FDA within 48 business hours
for inspection upon request. After 12 months from the date of their creation,
upon FDA’s request such records must be made available for inspection within a
reasonable time. * The letter of authorization refers to “Laboratories
certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA),
42 U.S.C. §263a, that meet requirements to perform high complexity tests” as
“authorized laboratories.”
Ezplex SARS-CoV-2 G Kit
Page 17 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
XVI. Performance Evaluation
A. Analytical Sensitivity (Limit of Detection) The limit of detection was evaluated for both upper and lower respiratory specimens. Negative clinical nasopharyngeal swabs collected in VTM and negative sputum matrix were used as the background matrices to prepare the samples. SARS-CoV-2 genomic RNA from Vircell (MBC137-R) was spiked into the negative clinical matrices at concentrations of 5, 2.5, 1.25, 0.625, and 0.3125 copies/uL. A total of 20 replicates per dilution were extracted using the QIAamp® DSP Virus Spin Kit and then tested on both the CFX96 Dx and ABI7500 thermocyclers. The preliminary LoD was then confirmed by testing 20 additional extraction replicates. The limit of detection was estimated as the concentration where the overall assay result yielded 95% positivity.
Target
CFX96
Nasopharyngeal
Sputum
ABI 7500
Nasopharyngeal
Sputum
RdRp
0.8 copies/uL
0.64 copies/uL
1 copies/uL
1 copies/uL
N
1 copies/uL
1 copies/uL
1 copies/uL
0.64 copies/uL
Overall LOD
1 copies/uL
1 copies/uL
1 copies/uL
1 copies/uL
B. Analytical Sensitivity (Inclusivity) An in silico analysis comparing the primer and probe sequences from the EzplexSARS-CoV-2 G Kit against all SARS- CoV-2 sequences deposited in public databases (NCBI and GISAID) as of September 9, 2020 was conducted. The in silico analysis through reference sequences, generated the following data:
Target SARS-CoV-2 Virus
Gene
RdRp (NCBI, N=5000)
(GISAID, N=5204)
N (NCBI, N=5000)
(GISAID, N=5204)
Primer/Probe Forward Primer Reverse Primer
Probe
Forward Primer Reverse Primer
Probe
Percent Identities 100 % 100 % 100 %
100 % 100 %
100 %
C. Analytical Specificity 1. Cross Reactivity Nucleic Acid from a total of 24 species of microorganisms that are likely to be found in clinical respiratory specimens were tested with the Ezplex assay. Each species was tested in triplicate at the concentrations indicated in the table below. No cross reactivity was observed.
Ezplex SARS-CoV-2 G Kit
Page 18 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Microorganism
Adenovirus
Human metapneumovirus Human parainfluenza virus 1 Human parainfluenza virus 2
Human parainfluenza virus 3 Human parainfluenza virus 4
Influenza A virus Enterovirus 71 type Human respiratory syncytial
virus A Human respiratory syncytial
virus B Human rhinovirus
Chlamydophila pneumoniae
Haemophilus influenzae
Concentration 1X104 copies/uL 1X106 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL
Microorganism
Legionella pneumophila
Mycobacterium tuberculosis
Streptococcus pneumoniae
Bordetella pertussis
Mycoplasma pneumoniae
Candida albicans
Staphylococcus aureus Human coronavirus OC43 Human coronavirus NL63 Severe a
cute respira tory
syndrome Middle Ea st respiratory
syndrome
Concentration 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1X104 copies/uL 1.41X106 copies/uL 1X106 copies/uL 1X106 copies/uL 1X106 copies/uL
2. Cross Reactivity (in silico) A total of 28 organisms were selected to assess the potential for cross reactivity with the primers/probes included in the Ezplex Assay. This analysis was conducted using the NCBI blast database. The percent homology with each primer and probe used in the Ezplex is displayed in the table below:
RdRP homology(%)
N homology(%)
No.
Organisms
F primer Probe R primer F primer
Probe
R primer
1
Human coronavirus 229E*
89%
None
70%
58.8%
41.6%
50%
2
Human coronavirus OC43*
None
None
40%
94%
41.6%
50%
3 Human coronavirus HKU1* 91.6% None 76.6% 52.9%
37.5%
60%
4
Human coronavirus NL63
33.3% None
40%
52.9%
37.5%
60%
5
SARS-coronavirus **
75%
None 93.3% 100% 83.3%
80%
Ezplex SARS-CoV-2 G Kit
Page 19 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
6
MERS-coronavirus*
7
Adenovirus 71
8
Human Metapneumovirus
9
Parainfluenza virus 1
10
Parainfluenza virus 2
11
Parainfluenza virus 3
12
Parainfluenza virus 4
13
Influenza A
14
Enterovirus group
15
Respiratory syncytial virus
16
Rhinovirus
17
Chlamydia pneumoniae
18
Haemophilus influenzae
19
Legionella pneumophila*
20 Mycobacterium tuberculosis
21
Streptococcus pneumoniae
22
Streptococcus pyogenes
23
Bordetella pertussis
24
Mycoplasma pneumoniae
25 Pneumocystis jirovecii (PJP)
26
Candida albicans*
27
Pseudomonas aeruginosa
28
Staphylococcus group*
60% 37.5% 45.8% 33.3% None None 50% 54.1% 50% None 50% 50% 58.3% 62.5% 50% 58.3% 54.1% None 50% 62.5% 62.5% 62.5% 70.8%
None None None None None None None None None None None None None None None None None None None None None None None
90% 30% 36.6% 33.3% None None 36.6% 43.3% 46.6% None 46.6% 43.3% 43.3% 50% None 43.3% 43.3% None 43.3% 76.6% 53.3% 46.6% 50%
58.8% 52.9% 58.8% 52.9% None None 64.7% 76.4% 70.5% None 70.5% 64.7% 76.4% 82.3% 64.7% 76.4% 76.4% None 58.8% 64.7% 88.2% 76.4% 82.3%
45.8% 41.6% 45.8% 37.5% None None 41.6% 62.5% 62.5% None 62.5% 54.1% 54.1% 54.1% 62.5% 54.1% 50% 54.1% 45.8% 62.5% 54.1% 70.8% 79.1%
60% 50% 55% 45% None None 50% 60% 70% None 70% 60% 70% 65% 60% 70% 65% 70% 55% 65% 70% 65% 70%
- For the organisms marked with *, relatively high homology was observed (more than 80%) for one oligo in the primer/probe set. However, in order for an amplification product to be generated using the PCR mechanism, both of the primers and the probe must anneal to the target sites on the gene. Therefore, cross-reactivity with these organisms is not expected.
- For the SARS-coronavirus organism marked with **, more than 80% homology
was found for all three oligos for the N gene. However, the interpretation
algorithm of Ezplex states that only results where both the RdRp and N genes
show amplification within 40 Ct are considered positive. Because >80% homology
was not seen in all three primer/probe oligos for the RdRp gene, false
positive results are not expected to occur.
3. Interference The effect of endogenous (Albumin (0.24g/mL), Hemoglobin (0.2g/mL), Bilirubin (0.05mg/mL) ) and exogenous (Mupirocin(20mg/mL), Tobramycin (80mg/mL), Zanamivir (250ug/mL)) interfering substances on assay performance was evaluated. Samples containing
Ezplex SARS-CoV-2 G Kit
Page 20 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
these substances were tested in triplicate with and without SARS-CoV-2 virus
material at a concentration of ~3XLoD. No interference was observed as
indicated by a less than 1 mean Ct differential between samples with and
without interferent for both gene targets in all cases.
D. In Silico Analysis In silico analysis for all sequences of SARS-CoV-2,
available from NCBI and GISAID databases, was conducted by mapping the
individual primers and probes of the Ezplex assay. As of Sep 09, 2020, in
silico analysis through GISAID (n =5204) and NCBI (n = 5000) sequences
generated data as shown in the table below.
Gene RdRp
N
Primer(Probe)
Probe Primer Forward Primer Reverse Primer
Probe Primer Forward Primer Reverse Primer
Homology(%)
NCBI(N=5000)
GISAID(N=5204)
100
100
100
100
100
100
100
100
100
100
100
100
E. Clinical Evaluation The purpose of this clinical evaluation was to assess the clinical performance of the Ezplex SARS-CoV-2 G Kit against an EUA- authorized comparator assay. In the clinical evaluation study, left-over archived specimens from symptomatic patients suspected of COVID-19 infection were tested. Specimens were previously subjected for SARS-CoV-2 testing and then stored at a clinical laboratory in South Korea prior to including in this study. A total of 30 positive and 30 negative clinical specimens confirmed by an EUA-authorized comparator Assay were tested with the investigational Ezplex assay. These 60 total specimens consisted of 15 positive and 15 negative upper respiratory (nasopharyngeal/oropharyngeal swabs collected in VTM) specimens and 15 positive and 15 negative sputum specimens. For this study, the specimens were extracted using the QIAamp® DSP Viral RNA mini Kit (Qiagen). Real-time RT-PCR was performed using the CFX96 Dx Real-time PCR Instrument (Bio-Rad). The results from testing of individual specimens are shown as below.
Upper Respiratory Specimens
Positive
Ezplex Negative
Total Positive agreement
(95% CI) Negative agreement
(95% CI)
Original Test of Record
Positive Negative Total
15
0
15
0
15
15
15
15
30
100 % (78.2 ~ 100 %)
100 % (78.2 ~ 100 %)
F. Pooling Verification
Lower Respiratory Specimens
Positive
Ezplex Negative
Total Positive agreement
(95% CI) Negative agreement
(95% CI)
Original Test of Record
Positive Negative Total
15
0
15
0
15
15
15
15
30
100 % (78.2 ~ 100 %)
100 % (78.2 ~ 100 %)
Ezplex SARS-CoV-2 G Kit
Page 21 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
For the pooling verification study, a total of 180 upper respiratory specimens were collected and initially tested with Ezplex and the comparator EUA- authorized real-time PCR assays. These specimens consisted of 30 comparator positive and 150 comparator negative specimens. Testing with the Ezplex assay revealed concordant results for all specimens. Each single positive specimen was pooled together with 4 negative specimens (N=5) to create the positive pools. The negative pools were prepared by combining 5 negative specimens(N=5). This created a total of 30 positive and 30 negative pools. These pools were prepared by aliquoting 50uL of each specimen into a sterile tube to make a final volume of 250uL. For this study, extraction was performed using the QIAamp® DSP Viral RNA Mini Kit (Qiagen). Real-time RT-PCR was performed using the CFX96 Dx Real-time PCR Instrument (Bio-Rad). The results from testing of pooled specimens are shown below for each target.
- RdRp Gene Result
SARS-CoV-2 Virus(RdRp)
37< Ct 40
Pooled Testing
Positive 34< Ct 37 Ct 34
Negative
Total
Positive agreement (95%CI)
Negative agreement (95%CI)
- N Gene Result
Individual Testing
Expected Positive 37< Ct 40 34< Ct 37 Ct 34
Negative
1
4
–
1
2
2
0
–
–
20
0
0
0
30
30
30
100 % (88.4 ~ 100 %)
100 % (88.4 ~ 100 %)
Total
30 30 60
SARS-CoV-2 Virus(N)
37< Ct 40
Pooled Testing
Positive 34< Ct 37 Ct 34
Negative
Total
Positive agreement (95%CI)
Negative agreement (95%CI)
Individual Testing
Expected Positive 37< Ct 40 34< Ct 37 Ct 34
Negative
4
1
–
–
3
1
0
–
–
21
0
0
0
30
30
30
100 % (88.4 ~ 100 %)
100 % (88.4 ~ 100 %)
Total
30 30 60
These results indicate that all individually positive specimens were also detected when present in a 5-sample pool. Among the 30 positive specimens, 8 weakly positive specimens were included in the verification.
Ezplex SARS-CoV-2 G Kit
Page 22 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
The individual Ct values for these specimens were compared to the Ct value where the same specimen was pooled with 4 negative specimens, as indicated below.
Individual Result
No. RdRp(FAM) N(Cy5)
1
38.42
38.09
2
35.65
35.16
3
35.64
37.11
4
38.63
38.25
5
35.29
36.13
6
36.56
37.19
7
35.43
36.33
8
36.63
35.59
IC(HEX) 30.82 30.81 31.13 31.37 30.60 30.52 30.69 30.64
Pooled Result
RdRp(FAM) N(Cy5)
36.90
39.09
36.72
36.35
37.57
37.66
38.72
38.94
38.06
36.44
37.73
39.19
37.15
36.95
36.81
39.92
IC(HEX) 31.28 31.30 31.52 31.25 31.49 31.37 31.23 31.23
These data indicate that low positive samples are able to be detected when
present in 5 sample pools.
XVII. FDA SARS-CoV-2 Reference Panel Testing
The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded samples and a standard protocol provided by the FDA. The study included a range finding study and a confirmatory study for LoD. Blinded specimen testing was used to establish specificity and to confirm the LoD. The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded specimens and a standard testing protocol provided by the FDA. The extraction method and amplification instrument used were the QIAamp® DSP Viral RNA Mini Kit (62904) and the CFX96TM Dx Systems (1845097IVD) respectively. The results are summarized in the Table below.
Table: Summary of LoD Confirmation Result using the FDA SARS-CoV-2 Reference Panel
Reference Materials Provided by FDA
Specimen Type
Product LoD
CrossReactivity
SARS-CoV-2
Nasopharyngeal Swab
1,200 NDU/mL
N/A
MERS-CoV
in VTM
N/A
ND
NDU/mL = RNA NAAT detectable units/mL N/A: Not applicable ND: Not detected
Appendix A: Specimen Pooling-Determining Appropriate Strategy for
Ezplex SARS-CoV-2 G Kit
Page 23 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Implementation and Monitoring
Sample Pooling Monitoring (Laboratory Monitoring Part A) Before a pooling
strategy is implemented, a laboratory should determine the appropriate pool
size based on percent positivity rate in the testing population and pooling
testing efficiency (Table 1). The Ezplex SARS-CoV-2 assay has been validated
for n-sample pool sizes up to five samples per pool.
Table 1. Efficiency of pooling based on the positivity of SARS-CoV-2 RNA in individual samples (as an example)
Ezplex SARS-CoV-2 G Kit
Page 24 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
P, percent of positive
subjects in the tested
population
5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17% 18% 19% 20% 21% 22% 23% 24% 25%
nmaxefficiency (n corresponding to the maximal
efficiency)
5 5 4 4 4 4 4 4 3 3 3 3 3 3 3 3 3 3 3 3 3
Efficiency of n-sample pooling corresponding to nmaxefficiency (a
maximumincrease in the number of tested patients when Dorfman n- pooling
strategy used) 2.35 2.15 1.99 1.87 1.77 1.68 1.61 1.54 1.48 1.43 1.39 1.35
1.31 1.28 1.25 1.22 1.19 1.16 1.14 1.12 1.10
A.1 If Historical Data for Individual Specimens is Available
A.1.1 Positivity Rate of Individual Testing · Estimate positivity rate (P
individual) in the laboratory based on individual sample testing.
For this consider the 7-10 previous days and calculate the number of patients
tested during those days. P individual is the number of positive results
divided by the total number of tested patients during these 7-10 days.
A.1.2 Selection of test developer validated size of sample pools, n · Use P
individual and Table 1 to choose an appropriate validated pool size. Table 1
presents
the pool size with the maximum efficiency for the validated pool sizes and
positivity rates. If the positivity rate (P individual) is in Table 1, choose
n from Table 1 which corresponds to the maximum efficiency (F). · If P
individual in your laboratory does not correspond to the largest validated
pool size in
Ezplex SARS-CoV-2 G Kit
Page 25 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
Table 1, the pool size with maximum efficiency for this positivity rate was
not validated and you should choose the maximum n which was validated. For
example, for the calculation of efficiency of 5-sample pooling, using formula
F=1/ (1+ 1/5-(1-P)5), when P individual is 1%, the efficiency F is 3.46 for
n=5. It means that 1,000 tests can cover testing of 3,460 patients on average.
· If P individual is greater than 25%, then pooling patient samples is not
efficient and should not be implemented.
A.2 If Historical Individual Data for Individual Specimens is Unavailable
If historical data from the previous 7-10 days is unavailable, the maximum
pool size validated in the EUA and any smaller pool sizes can still be
implemented, as the EUA test has been validated for the maximum pool size-
specimen pooling. However, note that without P individual, the laboratory may
choose a pooling size that does not maximize pooling efficiency.
Sample Pooling Monitoring (Laboratory Monitoring Part B) After implementing a
n-sample pooling strategy, calculate the percent positivity rate (P pool)
based on n sample pooling strategy periodically using the data from pooled
samples from the previous 7-10 days.
B.1 If Historical Data for Individual Specimens is Available
If historical data for individual specimens is available, compare P pool to P
individual periodically. If P pool is less than 85% of P individual (P pool <
0.85 × P individual), it is recommended that: · The pool size be adjusted to
maximize pooling efficiency according to Table 1 above and
the new n should not be more than the test developer validated maximum n in
the EUA. · If P pool is greater than 25%, pooling of patient samples is not
efficient and should be
discontinued until the percent positivity rate decreases.
B.2 If Historical Data for Individual Specimens is Unavailable
· After implementing a n-sample pooling strategy, first calculate the
positivity rate (P poolinitial) based on n-sample pool size using the data
from testing pooled samples from the first 7-10 days.
o If P pool-initial is greater than 25%, pooling of patient specimens is not
efficient and should be discontinued until the percent positivity rate
decreases.
o If P pool-initial is less than or equal to 25%, pooling of patient specimens
can be continued.
· Continue to monitor n-sample pooling strategy by calculating the positivity
rate among patient samples during n-sample pooling (P pools-x) for subsequent
7-10* day period based on n-sample pool testing. (P pool-x) should be updated
daily using a moving average.
Compare P pool-initial to P pool-x periodically. If P pool-x is less than 90%
of P pool-initial (P pool-x <
Ezplex SARS-CoV-2 G Kit
Page 26 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
0.90 × P pool-initial), it is recommended that:
· The pool size be adjusted to maximize pooling efficiency, according to the
criteria in Table 1 above, and the new n should not be more than the test
developer validated maximum n in the EUA.
· If P pool is greater than 25%, pooling of patient samples is not efficient
and should be discontinued until the percent positivity rate decreases.
- It is recommended that P individual be calculated from the previous 7-10 days, while P pool and P pool-x are calculated from data collected during a 7-10 day time frame. However, when determining if 7-10 days is appropriate, take into consideration the laboratory testing volume and percent positivity, among other factors. Note that if the number of individual or pooled positive results collected during a given time frame is less than 10, P individual, P pools, and P pool-x may not be representative of the percent positivity in the testing population and the laboratory may want to consider extending the testing time period to increase the chance of capturing positives.
Appendix B: Additional Label
For the ThermoFisher ABI 7500 Real-time PCR Instrument
Please print and place this label on the front panel of the instrument. If the instrument includes labeling indicating “For Research Use Only”, please cover with the below “Emergency Use Only” labeling. The instrument should retain this labeling throughout the EUA use of the Ezplex SARSCoV-2G Kit.
Emergency Use Only This instrument is
authorized for use with the Ezplex SARS-CoV-2 G
Kit
XVIII. References
1. World Health Organization. Q&A on coronaviruses (COVID-19). April 17,
2020. World Health Organization Web site https://www.who.int/news-
room/q-a-detail/q-a-coronaviruses. Accessed October 8, 2020.
Ezplex SARS-CoV-2 G Kit
Page 27 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
2. Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019ncov/prevent-getting-sick/how-covid-
spreads.html. Accessed June 17, 2020.
3. Centers for Disease Control and Prevention. Coronavirus Disease
2019-(COVID-19) in the U.S. Updated October 7, 2020. Centers for Disease
Control and Prevention website site https://www.cdc.gov/coronavirus/2019-ncov
/cases-in-us.html. Accessed October 8, 2020.
4. Centers for Disease Control and Prevention. Coronavirus Disease 2019
Information for Travel. Page last reviewed August 21, 2020. Centers for
Disease Control and Prevention website.
https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html. Accessed
October 8, 2020.
5. Centers for Disease Control and Prevention. Coronavirus Disease
2019-(COVID-19) Situation Summary. Update October 7, 2020.
https://www.cdc.gov/coronavirus/2019-ncov/summary.html. Accessed October 8,
2020.
6. Clinical & Laboratory Standards Institute. Document M29 Protection of
Laboratory Workers from Occupationally Acquired Infections. CLSI website.
https://clsi.org/standards/products/microbiology/documents/m29. Accessed
October 8, 2020.
XIX. Symbols and Information
Symbol
Meaning Stora ge Temperature
Expiration date
Ca talogue Number
Lot Number
Contents sufficient for
Authorized Representative in the European Community
Symbol
Meaning In-Vitro Diagnostic
Medical Devices Product User Manual
Ma nufacturer Keep away from sunlight
(P+P)
For prescription use only
XX. Technical and Customer Support
Ezplex SARS-CoV-2 G Kit
Page 28 / 29
IFU013 (rev.3, April 2021)
Ezplex SARS-CoV-2 G Kit
For Technical Support, please contact our Genetree Technical Support team.
Before contacting Genetree Technical Support, collect the following
information:
· Product name · Lot number · Software version
o Email for Technical Support: technicalsupport@smlgenetree.com o Email for
Customer Support: customersupport@smlgenetree.com o Tel: +82-2-2057-7900 o
Fax: +82-70-7425-3950 o Mailing address: 225 Baumoe-ro, Seocho-gu, Seoul,
06740 Republic of Korea o Website: http://www.smlgenetree.com
· ©2021 SML Genetree. All rights reserved. · Ezplex is a registered trademark
of SML Genetree and/or its subsidiaries in the United
States and/or other countries. · All other trademarks that may appear in this
package insert are the property of their
respective owners.
Obelis S.A. Bd. Général Wahis, 53, B-1030 Brussels, Belgium
SML Genetree Co. Ltd. 255 Baumoe-ro, Seocho-gu, Seoul, 06740, Republic of
Korea SML Genetree Sciences, Inc. 400 Concar Drive, Suite 03-160 San Mateo, CA
94402
Ezplex SARS-CoV-2 G Kit
Page 29 / 29
IFU013 (rev.3, April 2021)
References
- HHS Accessibility & Section 508 | HHS.gov
- SML Genetree
- M29A4: Protecting Lab Workers from Workplace Infections
- Coronavirus disease (COVID-19)
Read User Manual Online (PDF format)
Read User Manual Online (PDF format) >>